Charles River Laboratories International, Inc.

NYSE:CRL

Medical - Diagnostics & Research

Healthcare
$333.25 -1.33%

-$2.45 today

Market cap
$15.97B
Beta
1.45
P/E (TTM)
-48.3
EPS (TTM)
-$3.77
52W Low $144.26High $228.88

Volume 0.52M

Average 0.86M

CRL Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Charles River Laboratories International, Inc.NYSE: CRL

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 36.2%

Gross margin was 36.2% in Q2 FY2026, up 1.6 pp from a year earlier. On a trailing-twelve-month basis it was 32.2%, down 0.2 pp year over year. Over 3 fiscal years it narrowed by 6.3 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
36.2%+8.1 pp QoQ
Last fiscal yearDec 2025
30.5%-2.4 pp YoY
LTMJun 2026
32.2%-0.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.6 pp——
1 year-2.4 pp——
3 years-6.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
30.5%
Year-over-year change
-2.4pp

Gross Margin vs competitors

How CRL compares with its peers on the latest reported figures

  • CRL's LTM Jun 2026 gross margin of 32.2% is the 2nd highest of the 4 companies compared; the peer median is 29.1%.
  • Its year-over-year change of -0.2 pp is the highest of 4, against a peer median of -2.1 pp.
  • Over three fiscal years its change of -6.3 pp compares with a peer median of +0.4 pp.
CRL Competitors Peer median
Gross Margin for CRL and competitors
Company Period LTM level YoY 3-year change
CERTCertara, Inc.LTM Mar 202658.1% -2.1 pp+1.0 pp
CRLCharles River Laboratories International, Inc.LTM Jun 202632.2% -0.2 pp-6.3 pp
MEDPMedpace Holdings, Inc.LTM Sep 202629.1% -2.0 pp+0.4 pp
ICLRICON Public Limited CompanyLTM Jun 202621.8% -6.7 pp-2.2 pp
Peer median (excluding CRL) 29.1%-2.1 pp+0.4 pp

Competitors are the stored peer set for CRL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.54B3.98B4.13B4.05B4.02B
Cost of Revenue2.21B2.51B2.63B2.72B2.79B
Gross Profit1.33B1.46B1.5B1.33B1.23B
Gross Margin37.7%36.8%36.4%32.9%30.5%
Research & Development00000
Selling, General & Admin619.92M665.1M747.86M751M743.07M
Operating Expenses744.78M811.68M885.3M1.1B717.73M
Depreciation & Amortization265.54M303.87M314.12M361.74M403.31M
EBITDA820.16M986.15M1.03B581.14M410.84M
EBITDA Margin23.2%24.8%25.0%14.3%10.2%
Operating Income589.86M650.98M617.26M227.35M507.84M
Operating Margin16.7%16.4%14.9%5.6%12.6%
Interest Income652K780K5.2M8.58M4.94M
Interest Expense73.91M59.29M136.71M126.29M107.03M
Other Income / Expenses(109.15M)(27.99M)(35.98M)(134.23M)(607.34M)
Income Before Tax480.71M622.99M581.28M93.11M(99.5M)
Pre-Tax Margin13.6%15.7%14.1%2.3%-2.5%
Income Tax Expense81.87M130.38M100.91M67.82M42.66M
Net Income390.98M486.23M474.62M10.3M(144.34M)
Net Margin11.0%12.2%11.5%0.3%-3.6%
EPS (Basic)7.779.579.270.20(2.91)
EPS (Diluted)7.609.489.220.20(2.91)
Weighted Avg Shares50.29M50.81M51.23M51.38M49.56M
Weighted Avg Shares (Diluted)51.43M51.3M51.45M51.63M49.56M

Charles River Laboratories International, Inc.

NYSE:CRL

Intrinsic Alpha fair value

Locked

Current Price

$333.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.